It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Myelin regeneration (remyelination) is essential to prevent neurodegeneration in demyelinating diseases such as Multiple Sclerosis, however, its efficiency declines with age. Regulatory T cells (Treg) recently emerged as critical players in tissue regeneration, including remyelination. However, the effect of ageing on Treg-mediated regenerative processes is poorly understood. Here, we show that expansion of aged Treg does not rescue age-associated remyelination impairment due to an intrinsically diminished capacity of aged Treg to promote oligodendrocyte differentiation and myelination in male and female mice. This decline in regenerative Treg functions can be rescued by a young environment. We identified Melanoma Cell Adhesion Molecule 1 (MCAM1) and Integrin alpha 2 (ITGA2) as candidates of Treg-mediated oligodendrocyte differentiation that decrease with age. Our findings demonstrate that ageing limits the neuroregenerative capacity of Treg, likely limiting their remyelinating therapeutic potential in aged patients, and describe two mechanisms implicated in Treg-driven remyelination that may be targetable to overcome this limitation.
Factors limiting CNS remyelination with age are poorly understood. Here the authors show that aged Treg lose capacity to support CNS remyelination in mice, which can be restored in a young environment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Institute for Health and Biomedical Sciences of Alicante (ISABIAL), Alicante, Spain (GRID:grid.513062.3) (ISNI:0000 0004 8516 8274); Instituto de Neurosciencias CSIC-UMH, San Juan de Alicante, Alicante, Spain (GRID:grid.466805.9) (ISNI:0000 0004 1759 6875)
2 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
3 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Utrecht University, Division of Pharmacology, Institute for Pharmaceutical Sciences, Utrecht, The Netherlands (GRID:grid.5477.1) (ISNI:0000 0000 9637 0671)
4 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Queen’s University Belfast, Patrick G Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
5 University of Cambridge, Department of Pathology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Babraham Institute, Cambridge, UK (GRID:grid.418195.0) (ISNI:0000 0001 0694 2777)
6 Institute for Health and Biomedical Sciences of Alicante (ISABIAL), Alicante, Spain (GRID:grid.513062.3) (ISNI:0000 0004 8516 8274); Instituto de Neurosciencias CSIC-UMH, San Juan de Alicante, Alicante, Spain (GRID:grid.466805.9) (ISNI:0000 0004 1759 6875)
7 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); CRUK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
8 Instituto de Neurosciencias CSIC-UMH, San Juan de Alicante, Alicante, Spain (GRID:grid.466805.9) (ISNI:0000 0004 1759 6875)
9 University of Cambridge, Department of Clinical Neurosciences, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Karolinska Institute, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
10 University of Southern Denmark, Institute of Molecular Medicine, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170); Danish Institute for Advanced Study (DIAS), Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170)
11 Altos Labs - Cambridge Institute of Science, Granta Park, Cambridge, UK (GRID:grid.10825.3e)
12 University of Cambridge, Department of Pathology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
13 Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); University of Southern Denmark, Institute of Molecular Medicine, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170); Danish Institute for Advanced Study (DIAS), Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170); Odense University Hospital, Department of Clinical Genetics, Odense, Denmark (GRID:grid.7143.1) (ISNI:0000 0004 0512 5013)